RxDoctor Payments Data

Barbara Moran-Faile, MD

Cardiovascular Disease · Greenville, SCNPI 1396737995

Payments from drug & device makers

$415in general payments, 2019–2025

Across 25 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$102
  • Amgen$61
  • Novo Nordisk$49
  • Boston Scientific$38
  • Novartis$36
  • Daiichi Sankyo Inc.$25
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$415 in reported general payments places this provider in the 10th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$277,218
Medicare patients
1,085
Services billed
3,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban953$1,000,642
XareltoRivaroxaban237$290,275
EntrestoSacubitril/Valsartan243$247,995
Repatha SureclickEvolocumab159$130,615
MultaqDronedarone Hcl67$94,663
JardianceEmpagliflozin70$76,086
FarxigaDapagliflozin Propanediol36$36,923
CorlanorIvabradine Hcl18$20,249
VascepaIcosapent Ethyl31$18,637
Ranolazine ErRanolazine91$13,544
BrilintaTicagrelor29$13,432
Metoprolol Succinate912$12,179
Praluent PenAlirocumab16$11,261
NexletolBempedoic Acid13$10,238
Repatha SyringeEvolocumab18$9,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$1,000,642953 claims
Johnson & JohnsonXarelto$22$290,275237 claims
NovartisEntresto$36$247,995243 claims
Sanofi-aventis U.S. LLCMultaq$17$94,66367 claims
AmgenCorlanor$61$20,24918 claims
Esperion Therapeutics, Inc.Nexletol$13$10,23813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →